Professional
Added to YB: 2025-01-31
Pitch date: 2025-01-07
BVNRY [bullish]
Bavarian Nordic A/S
+7.93%
current return
Author Info
No bio for this author
Company Info
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
Market Cap
$15.2B
Pitch Price
$9.08
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.47
P/E
13.67
EV/Sales
2.21
Sector
Biotechnology
Category
growth
Protean Small Cap New Position: Bavarian Nordic A/S
BVNRY: Danish vaccine co. Strong travel vaccine franchise (rabies, TBE) growing. TBE benefits from climate change. Potential for acquisitions in neglected travel vaccine segment. Jynneos (smallpox/monkeypox) adds optionality. Consolidating production to improve margins by 2025. Reduced risk profile with growing core business.
Read full article (1 min)